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RESUMEN
Objetivo: El objetivo de este estudio es investigar la correlación entre la polifarmacia y los síntomas 
depresivos en adultos hospitalizados mayores de 65 años.
Pacientes y métodos: Se obtuvo la historia clínica y los datos actuales de tratamiento de las historias 
clínicas. Se utilizó la puntuación de la prueba Mental Abreviado (AMTS) para excluir a los pacientes con 
demencia. La Escala de Depresión Geriátrica (GDS) se utilizó para evaluar los síntomas depresivos. Se 
usaron coeficientes Pearson y Spearman para determinar la relación entre las variables.
Resultados: Se incluyó a un total de 206 individuos. El número medio de medicamentos tomados por 
los individuos fue de 6,9 ± 2,7 y la puntuación media GDS fue de 4,9 ± 3,4 puntos. Los síntomas de 
depresión (GDS puntuación> 5 puntos) se observaron en 68 (33,0%) individuos. La puntuación GDS de 
una correlación positiva con el número de medicamentos que se usaron (R = 0,74; P = 0,0001), el número 
de condiciones crónicas (R = 0,78; P = 0,001), y quejas de dolor (Z = 7,94; P = 0,0001). Se observó una 
asociación significativa entre la partitura GDS y el uso de los siguientes medicamentos: estatinas, agentes 
citostáticos, corticoesteroides, benzodiazepinas, glucósidos cardíacos, los fármacos no esteroides antiin-
flamatorios, relajantes musculares, medicamentos sin psicotrópicas con propiedades anticolinérgicas, y 
de acción central analgésicos (todos P <0,05).
Conclusiones: Nuestro estudio indica que la polifarmacia se correlaciona positivamente con la presencia 
de síntomas depresivos en pacientes geriátricos. Se identificó una serie de medicamentos asociados con 
una mayor prevalencia de síntomas depresivos; Sin embargo, estas relaciones requieren un examen más 
detenido.
Palabras clave: adulto mayor; efectos adversos de la droga; salud mental; psiquiatría.
ABSTRACT
Aim: The aim of this study was to investigate the correlation between polypharmacy and depressive 
symptoms in hospitalized adults aged over 65 years.
Patients and methods: We obtained medical history and current treatment data from clinical records. 
We used the Abbreviated Mental Test Score (AMTS) to exclude patients with dementia. The Geriatric 
Depression Scale (GDS) was used assess depressive symptoms. Pearson and Spearman coefficients were 
used to determine the relationship between variables.
Results: A total of 206 individuals were included. The average number of medications taken by the indi-
viduals was 6.9 ± 2.7 and the average GDS score was 4.9 ± 3.4 points. Depressive symptoms (GDS score 
>5 points) were observed in 68 (33.0%) individuals. GDS score positively correlated with the number 
of medications used (R = 0.74; P = 0.0001), the number of chronic conditions (R = 0.78; P = 0.001), and 
pain complaints (Z = 7.94; P = 0.0001). A significant association between GDS score and the use of the 
following medications was observed: statins, cytostatic agents, corticosteroids, benzodiazepines, cardiac 
glycosides, non-steroidal anti-inflammatory drugs, muscle relaxants, non-psychotropic drugs with an-
ticholinergic properties, and centrally acting analgesics (all P < 0.05).
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Conclusions: Our study indicates that polypharmacy is positively 
correlated with the presence of depressive symptoms in geriatric 
patients. We identified a number of medications associated with 
a higher prevalence of depressive symptoms, however these rela-
tionships require further examination.
Key words: elderly; adverse drug effects; mental health; psychia-
try.
INTRODUCTION
The process of aging has perplexed mankind since ancient 
times, but it has never been subject to as extensive consid-
eration as it is now. The aged population continues to rise 
worldwide as a result of demographic transition (ie, the re-
duction in mortality resulting from civilizational advance-
ment, and concomitant decline in fertility rates). Accord-
ing to Eurostat, the proportion of individuals aged over 65 
years currently exceeds 18% of the European Union popu-
lation, and is estimated to reach 28% by 2060.1 As a con-
sequence, clinicians can expect to increasingly face issues 
inextricably associated with senility, such as coexistence 
of several chronic conditions in an individual, functional 
impairment, and the necessity to use multiple medications.
According to literature, depression is the most prevalent 
mental disorder in the elderly affecting up to 20% of indi-
viduals in the community setting,2 and 5–58% of geriatric 
patients treated in general hospitals.3 However, available 
data on the prevalence of depression in the elderly are in-
consistent, and some numbers may be underrated given 
the diagnostic challenges in this age group. Diagnosis may 
be hindered by communication difficulties that stem from 
hearing problems or cognitive impairment, as well as the 
presence of other disorders with somatic symptoms resem-
bling those of depression. Furthermore, lowered mood and 
psychomotor retardation in the elderly are often erroneous-
ly viewed as part of the aging process, which contributes to 
underreporting of the disease and, as a consequence, the 
lack of proper treatment.
A host of predisposing factors for geriatric depression have 
been identified to date, including: decreased functional 
capacity associated with chronic physical illnesses, a low 
degree of social support, widowed or divorced status, and 
polypharmacy.4 As the goal of care shifts from further ex-
tending the life span to improving the quality of living, we 
now look more into the means of reducing morbidity and 
maintaining independence in the elderly population. Due 
to the high prevalence of multiple medication therapies, as 
well as altered drug metabolism attributable to the old age, 
particular attention is being given to the effects of medica-
tions on cognition and geriatric syndromes, in addition to 
their efficacy and safety measures. According to some au-
thors, side effects of pharmacotherapy contribute to up to 
30% of hospitalizations in individuals aged over 70 years. 
In this group of patients, central nervous system (CNS) 
disorders comprise approximately one third of all adverse 
drug reactions.5
This observational, cross-sectional study was designed to 
investigate the relationship between polypharmacy and 
depressive symptoms in adults over 65 years of age in a 
hospital setting. We also aimed to establish whether a par-
ticular therapeutic class of medication was associated with 
increased prevalence of depressive symptoms in this popu-
lation.
MATERIAL AND METHODS
Subjects and ethical approval
Inpatients aged over 65, hospitalized for three or more days, 
normally responsive and verbally coherent, who scored 
the minimum of seven points on the Abbreviated Mental 
Test Score (AMTS) were eligible for enrolment. Individu-
als previously diagnosed with dementia or other psychi-
atric disorders, receiving antipsychotic or antidepressant 
medication, and those reporting a traumatic event such as 
serious accident or bereavement within the preceding year 
were excluded. Ethics approval was obtained from the Eth-
ics Committee of the Silesian Medical University, Katowice, 
Poland (reference number KNW/0022/KB/207/14). All 
patients obtained detailed information regarding the study 
and signed a written consent form prior to participation.
Information regarding patient’s history and current phar-
macological treatment were gathered by a clinician based 
upon medical records. Material status, social contacts, de-
gree of physical dependence, and prevalence of pain were 
determined according to self-report. Nutritional status was 
assessed using Nutritional Risk Screening (NRS) 2002 sys-
tem. Epidemiological methods were used to analyze col-
lected data.
Psychometric assessments
The Abbreviated Mental Test Score (AMTS) is a widely 
recognized diagnostic instrument used for initial as-
sessment of the mental status in elderly patients, and 
a valuable dementia-screening tool. It comprises ten 
questions, each scoring one point if answered correctly. 
A total score of less than seven or eight is suggestive of cog-
nitive impairment, although further testing is required to 
establish the diagnosis of dementia.6 The scale was adopt-
ed as part of a questionnaire applied to the general patient 
population in order to enroll study participants.
The Geriatric Depression Scale (GDS) was developed spe-
cifically to measure depressive symptoms in the elderly. A 
Short Form GDS consists of 15 yes/no questions concern-
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ing individual’s mood in the week prior to survey, ten of 
them suggest the presence of depressive symptoms if an-
swered affirmatively, the rest are indicative of depression 
if a negative answer is given. The results are interpreted as 
follows: 0-5 points – no depressive symptoms, 6-10 points 
– moderate depressive symptoms, 11-15 points – severe de-
pressive symptoms.7
Both scales employed in the study are generally available, 
validated in a Polish population, and did not require inves-
tigators’ consent before their use. Due to frequent cognitive 
impairment in elderly patients (the most common prob-
lems are with reading and writing), all questions were read 
to the participants during face-to-face interviews, and the 
investigator filled out the questionnaires.
Statistical methods
All statistical calculations were performed using STATIS-
TICA version 10.0 (StatSoft Inc., Tulsa, USA) and Microsoft 
Excel 2010 (Microsoft, Redmond, USA). Quantitative vari-
ables were expressed as mean ± standard deviation (SD) 
when normally distributed and otherwise as median (95% 
confidence interval, 95% CI). Qualitative variables were ex-
pressed as absolute numbers and percentage. Shapiro-Wilk 
normality test was used to determine distribution of quan-
titative variables. Differences between two independent 
groups were examined with Student’s t-test or Mann-Whit-
ney U-test. Pearson and Spearman correlation coefficients 
were used depending on whether the data was normally 
distributed to determine the strength and the direction of 
the relationship between variables. Additionally, a multi-
variable linear regression model was developed to assess 
the association between GDS score and select response 
variables. A P-value of less than 0.05 was considered sig-
nificant for all statistical analyses.
RESULTS
The study was conducted between September 2014 and Oc-
tober 2015 in three internal wards of two hospitals in the 
Silesian region of Poland. A total of 206 subjects were en-
rolled, with a mean age of 75.8 years (median = 75; 95% CI: 
74.9–76.7). A summary of patients’ characteristics is shown 
in Table 1.
Table 1. Sociodemographic and clinical characteristics of the study group (n = 206)
Variable n %
Gender
Female
Male
121
85
58.7
41.3
Marital status
Widowed
In a relationship
Single
Divorced
105
90
9
2
51.0
43.7
4.3
1.0
Education
Vocational
Primary
Secondary
Tertiary
97
62
41
6
47.1
30.1
19.9
2.9
Living arrangements
Living with family
Independent
Nursing/residential home
158
47
1
76.7
22.8
0.5
Chronic disorders
Cardiovascular
Endocrine and metabolic
Musculoskeletal
Digestive
Genitourinary
Respiratory
Neurological
Neoplastic (malignant & benign)
Other
198
98
60
52
46
39
26
25
19
96.1
47.6
29.1
25.2
22.3
18.9
12.6
12.1
9.2
Pain complaints 155 75.2
aMann-Whitney U-test, SD: standard deviation, NSAIDs: non-steroidal anti-inflammatory drugs
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The overall mean GDS score was 4.9 (SD=3.4). Of the 68 
(33.00%) individuals presenting depressive symptoms 
(GDS score > 5), 45 (21.8%) were rated as moderate, and 23 
(11.2%) as severe. There was no statistically significant dif-
ference in the prevalence of depressive symptoms between 
genders (P = 0.4734). Pain was reported by 155 (75.2%) in-
dividuals. The GDS score was significantly higher (Z = 7.94, 
P = 0.0001, Mann-Whitney U-test) in individuals reporting 
pain (median = 5.0; 95% CI: 5.3–6.3) compared to those 
without (median = 2.0; 95% CI: 1.7–2.4).
The average number of medications taken was 6.9 (SD = 
2.7). The average number of chronic physical disorders 
was 3.6 (median = 3.0; 95% CI: 3.3–3.8). We observed a sig-
nificant association between the GDS score and the use of 
statins, cytostatic agents, corticosteroids, benzodiazepines, 
cardiac glycosides, non-steroidal anti-inflammatory drugs 
(NSAIDs), muscle relaxants, non-psychotropic drugs with 
anticholinergic properties, and centrally acting analgesics 
(all P < 0.05; Table 2).
Table 2. Geriatric Depression Scale scores based on the type of medications used
Medication class Medication use
No Yes P-valuea
Statins (mean, SD) 4.8 (3.3) 5.6 (3.5) 0.0437
Cytostatic agents (mean, SD) 4.9 (3.3) 8.3 (3.0) 0.0072
Corticosteroids (mean, SD) 4.9 (3.3) 8.2 (3.4) 0.0021
Benzodiazepines (mean, SD) 4.9 (3.3) 8.1 (3.0) 0.0007
Cardiac glycosides (mean, SD) 4.9 (3.3) 7.1 (3.9) 0.0319
NSAIDs (mean, SD) 4.8 (3.3) 7.1 (3.4) 0.0001
Muscle relaxants (mean, SD) 4.9 (3.3) 9.9 (3.4) 0.0012
Non-psychotropic drugs with anticholinergic 
properties (mean, SD)
4.8 (3.3) 7.9 (3.3) 0.0001
Centrally acting analgesics (mean, SD) 4.8 (3.3) 7.4 (3.3) 0.0001
Figure 1. Correlation between the number of medications and Geriatric Depression Scale 
(GDS) (Spearman coefficient, R = 0.74, P = 0.0001)
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Figure 2. Correlation between the number of chronic conditions and Geriatric Depression 
Scale (GDS) (Spearman coefficient, R = 0.78, P = 0.0001)
Table 3. Relationship between GDS score and select response variables, multivariate 
analysis
B P-value
Gender -0,18 0,4963
Age -0,01 0,8738
Marital status -0,19 0,1656
Education 0,08 0,6654
Place of living (urban/rural area) -0,12 0,6446
Material status 0,61 0,0127
Social contacts 0,64 0,0047
Degree of physical independence -0,99 0,0001
Chronic pain complaints 0,62 0,0384
Nutritional status 0,01 0,6616
Number of chronic conditions 0,57 0,0001
Number of medications taken 0,18 0,0487
GDS: Geriatric Depression Scale; B: Unstandardized Coefficients
GDS score was positively correlated with the number of 
medications used (R = 0.74, P = 0.0001; Figure 1) and the 
number of chronic conditions (R = 0.78, P = 0.0001; Figure 
2). No correlation was found between depressive symp-
toms and age (R = 0.05, P = 0.1149). A multivariable linear 
regression model showed positive relationship between 
GDS score and the number of medication taken, number of 
chronic conditions, material impoverishment, social depri-
vation, and chronic pain complaints. The relationship was 
negative for degree of physical independence (Table 3).
DISCUSSION
The results of this study indicate that the use of multiple 
medications in geriatric patients is associated with an in-
creased rate of depressive symptoms. Although informa-
tion regarding the correlation between polypharmacy and 
depression in older populations is scarce, the results pre-
sented here are consistent with previous findings.8 For ex-
ample, an Italian study of 2,568 elderly patients previously 
showed that a GDS score of > 6 correlated positively with 
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the number of medication taken, which, together with pre-
vious assumptions, indicates that the relationship between 
depression and polypharmacy is bidirectional.9
The definition of polypharmacy varies across researchers, 
who arbitrarily set various cut-off points to characterize 
this phenomenon. Most simply, polypharmacy can be de-
scribed as the use of multiple medications or, to denote its 
pejorative connotation, the use of more medications than 
is clinically justified. Epidemiological data show that the 
average number of medications taken by community-
dwelling older adults ranges from 4 to 8.10 According to 
a population-based survey by Qato et al., 29% of patients 
aged 57 to 85 living in the community took >5 prescrip-
tion medications.11 The prevalence of polypharmacy in 
hospital setting is also high: the mean number of medica-
tions received in our study population was seven, which 
is similar to findings by other researchers. For example, a 
REPOSI study conducted in Italy showed that 51.9% of pa-
tients admitted to internal wards took more than 5 medica-
tions (4.9 on average) and the numbers increased further at 
discharge.12 Similarly, in a multicenter European study, the 
median number of medications taken by elderly hospital-
ized patients was 6 (IQR = 4.0–9.0).13
The use of extensive drug regimens reflects the need to 
treat multiple conditions that often coexist in the elderly. 
According to a systematic review by Marengoni et al., mul-
timorbidity (defined as the co-occurrence of two or more 
chronic disorders) affects from 55 to 98% of the elderly.14 
Major physical illnesses also constitute a risk factor for geri-
atric depression, and evidence exists that the prevalence of 
depressive syndromes is significantly higher in multimor-
bid individuals.15 Due to the overlap of depressive and so-
matic symptoms, assessing depression in older adults with 
multiple chronic conditions may be difficult and subject to 
confounding variables.
Patients reporting pain complaints are also more prone to 
misdiagnosis. Indeed, data regarding the correlation be-
tween pain and depressive symptoms are conflicting, and 
the attempts to measure pain perception threshold in de-
pressed and non-depressed individuals has led to contro-
versial results.16 In our study, individuals reporting pain 
complaints more often had depressive symptoms, which is 
consistent with some of the previous findings, especially 
those regarding chronic pain.17 This observation, however, 
raises a question regarding the correlation between depres-
sive symptoms and the use of analgesics (both non-ste-
roidal and centrally acting), as the experience of physical 
suffering may lead to an increased consumption of pain 
medications and therefore act as a confounder.
Polypharmacy is associated with a higher potential for 
pharmacological interactions and a greater possibility of 
prescribing cascade, that is, adding an extra medication to 
treat side effects wrongly interpreted as a new ailment.18 
The likelihood of adverse drug events (ADEs) rises along 
with the number of medications taken by the patient.19, 20 
According to an 11-year population-based observation by 
Bourgeois et al., individuals taking 5 or more medications 
were 88% more likely to experience an ADE compared to 
those taking less.21 Similar data were provided by other 
authors: a literature review by Fulton and Allen indicated 
the risk of ADEs correlated positively with the number of 
medications, and amounted to 82% when seven or more 
drugs were used.22 The particular vulnerability of geriatric 
patients to ADEs results from biological changes in organ 
functioning and diminished drug clearance.23 Therefore, 
due to age-related differences in pharmacokinetics and 
pharmacodynamics, therapeutic effects and pharmacologi-
cal interactions in the elderly are more difficult to predict.
When investigating relationships between medications and 
depression, we must consider a drug’s capacity to cause or 
exacerbate psychiatric disorders. This can be attributed to 
their specific action on neurotransmitters and receptors in 
the CNS, as well as their indirect impact on brain metabo-
lism via peripheral regulation. In addition to drugs that act 
primarily on the CNS, psychotropic properties are also ob-
served in other pharmaceuticals, including cardiovascular 
therapeutics, antiepileptics, antihistamines, analgesics, an-
timicrobial and chemotherapeutic agents, and cytostatics.24 
In our study, we found that many of the medications were 
associated with depressive symptoms in the elderly, as dis-
cussed below.
Muscle relaxants and other non-psychotropic drugs with 
anticholinergic properties were associated with a higher 
GDS score in this study. There is vast clinical evidence of 
the negative impact of anticholinergic drugs on cognition 
and functional performance in the elderly patients.25 Sev-
eral groups of non-psychotropic medications have been 
identified to worsen the existing cognitive dysfunction, 
cause alterations in the mental status, and induce psy-
chotic symptoms. These include: first-generation antihis-
tamines (promethazine, clemastine), alkaloid-containing 
antispasmodics (scopolamine, hyoscyamine), skeletal mus-
cle relaxants (baclofen, tolperisone), antimuscarinic agents 
for overactive bladder (oxybutynin, tolterodine), opioids 
(codeine, morphine, fentanyl), and some cardiovascular 
drugs (digoxin, captopril). On the other hand, the impact 
of the anticholinergic medications on the affective status is 
more complex. In light of physiological evidence suggest-
ing that hyperactivity of the cholinergic system contributes 
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to the pathogenesis of mood disorders, muscarinic recep-
tor antagonists have been investigated as antidepressants. 
For example, evidence that scopolamine administered in-
travenously exerts a rapid antidepressant effect and has 
a good safety profile was provided by a recent review of 
randomized controlled trials.26 However, more research is 
needed to confirm these findings, and unravel the impact 
of anticholinergic medications on depression in the elderly.
Cardiac glycosides (eg, digoxin) can also exert strong an-
ticholinergic effects.27 Due to diminished elimination rates, 
the risk of side effects with cardiac glycosides is increased 
in the elderly, although adverse reactions have also been 
observed at therapeutic concentrations. A number of case 
reports and small clinical trials support the notion that car-
diac glycosides may be associated with depression, but this 
was not confirmed in prospective studies.28 We recorded 
increased prevalence of depressive symptoms in patients 
treated with digoxin, yet this may partly result from gener-
ally high rates of depression in patients with heart failure.29
In our study, the GDS score was also increased with the 
use of corticosteroids, which is consistent with previous 
findings. Psychiatric side effects associated with systemic 
corticosteroid use are frequent, affecting approximately 
6% of patients.30 Most often they include agitation, anxi-
ety, insomnia, depressive disorders, delusion, mania, and 
confusional state, although delirium, aggressive behavior, 
cognitive impairment, and depersonalization have also 
been observed. Older age does not seem to be a predictor of 
a psychiatric risk; however, hypoalbuminemia, or the con-
current use of medications in geriatric patients that increase 
serum levels of corticosteroids, may heighten the probabil-
ity of psychiatric adverse reactions.31
Neurotoxicity of cytostatic and immunomodulating drugs 
used in the treatment of various types of cancer is well de-
scribed in medical literature (in both in vitro and in vivo 
studies), yet the underlying mechanisms have not been ful-
ly explained. The potential harmful effect of antineoplas-
tic agents on the nervous system can manifest as vascular 
complications, peripheral neuropathies, cognitive impair-
ment, and psychological distress, including depression.32 
According to literature, a decline in cognitive function and 
affective status is a frequent observation in a number of 
cancer survivors. The results of our study are in line with 
these findings, although the type and intensity of neuro-
logical side effects can be influenced by a range of other 
variables, such as the effect of concomitant conditions or 
individual patient’s characteristics.
Depressive symptoms may also be associated with a pro-
longed use of benzodiazepines or their withdrawal. Ben-
zodiazepine use in the elderly can precipitate the onset of 
depression;33 however, owing to rapid anxiolytic effects 
and good tolerance, they often constitute the first-line treat-
ment of mood and anxiety disorders. Despite numerous 
adverse consequences and high addictive potential, benzo-
diazepines are readily prescribed in geriatric populations 
to address depressive symptoms and sleeping disturbanc-
es. According to a meta-analysis by Sithamparanathan et 
al., chronic use of benzodiazepines in the elderly is asso-
ciated with a significant risk of ADEs, including depres-
sion, drowsiness, insomnia, and tremor.34 Additionally, 
pharmacological interactions with opioids, antihistamines, 
anticonvulsants, or atypical neuroleptics may result in pro-
longed or excessive sedation and confusional states, where-
as CYP3A4 and CYP2C19 inhibitors (eg, clarithromycin, 
ciprofloxacin, ketoconazole, dilitiazem, and omeprazole) 
increase benzodiazepines plasma concentrations and po-
tentiate their depressive effect on the CNS. We observed 
an association between benzodiazepine use and depressive 
symptoms in our patients. This, however, may not be attrib-
utable solely to the direct effect of medication and should 
be viewed against other factors, such as the duration of use, 
or affective status prior to the initiation of treatment.
Data regarding the possible role of statins in inducing de-
pression are contradictory.35 Nevertheless, a large body of 
evidence indicate that low lipid concentrations may predis-
pose to depressive symptoms, mainly by affecting seroto-
nin activity of the brain and inhibiting neuronal growth.36 
While statins effectively lower blood cholesterol levels and 
limit the risk of cardiovascular complications, the possible 
negative impact of long-term statin use on the patient’s 
psychological wellbeing should also be considered.37 In our 
study, significantly higher GDS scores were recorded in 
patients treated with statins (P = 0.0437). Interestingly, this 
was not observed for fibrates (P = 0.3785), which reduce 
blood triglyceride levels. Therefore, further research is nec-
essary to investigate the lipid-lowering drugs and various 
psychiatric outcomes.
In summary, understanding the complexity of geriatric 
care, as well as recognizing the possible negative effects of 
medications on the affective status, should help physicians 
to optimize drug regimens in the future. Other factors, such 
as socio-economic situation and accessibility of medicines, 
should also be encompassed in order to derive the desired 
benefit from pharmacotherapy. Although polypharmacy 
indisputably carries an increased risk of adverse events 
and affects adherence, this should not deter the physician 
from introducing a therapy that is beneficial for the patient. 
This is especially true when the potential advantages of the 
therapy outweigh the perils – as Albert Einstein once put it, 
«Everything should be made as simple as possible, but not sim-
pler.»
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Our study is subject to several limitations. First, the obser-
vation was conducted in a hospital setting and therefore 
its results should only be extrapolated to other elderly 
populations (community and nursing home dwellers) with 
caution. Second, the time of administration of the GDS, 
in regard to the patient’s admission and discharge, var-
ied among individuals, which could have influenced the 
recorded score. Third, GDS was developed as a screening 
tool for depression, and its definitive diagnosis can only be 
established following a thorough psychiatric assessment. 
Thus, given the exploratory character of this study and its 
relatively small patient sample, more research is needed to 
validate the results.
CONCLUSIONS
Maintaining independence and good quality of life is an 
important health outcome in the elderly and should be the 
goal of medical interventions. Our study indicates that the 
use of multiple medications, which has become a necessity 
in the face of the demographic changes and the growing 
proportion of seniors, is associated with depressive symp-
toms in geriatric patients. However, further research is re-
quired in order to confirm these associations and provide 
new guidelines to optimize drug regimens in the elderly.
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